You have free access to this content

Cancer

Cover image for Cancer

1 June 2010

Volume 116, Issue 11

Pages 2505–2727

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorial

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Patterns of questionable quality care in nonmuscle invasive bladder cancer (pages 2508–2510)

      John L. Gore and Michael P. Porter

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25020

      Understanding those factors associated with the rising cost of bladder cancer care may inform guidelines dedicated to defining the best bladder cancer practices. In the care of noninvasive bladder cancer patients, we have yet to define the services that are being underutilized or overutilized.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer (pages 2511–2518)

      Salah-Eddin Al-Batran and Jaffer A. Ajani

      Version of Record online: 18 MAR 2010 | DOI: 10.1002/cncr.25064

      A systematic MEDLINE search revealed that first-line chemotherapy tended to maintain, rather than improve, health-related quality of life (HRQoL) outcomes in patients with metastatic esophagogastric cancer. Increased efficacy was associated with improved HRQoL outcomes, whereas toxicity did not appear to directly affect HRQoL.

    2. You have free access to this content
      Human mesenchymal stem cells and their use in cell-based therapies (pages 2519–2530)

      Helena Motaln, Cristian Schichor and Tamara T. Lah

      Version of Record online: 18 MAR 2010 | DOI: 10.1002/cncr.25056

      • original image
      • original image
      • original image
      • original image

      The unpredictable ability of human mesenchymal stem cells (hMSCs) to spontaneously malignantly transform points toward the role of hMSCs in tumor development and puts into question hMSC use in cell-based therapies. However, emerging knowledge strongly favors their use in therapy and anticancer treatment.

    3. You have free access to this content
      Cervical cancer prevention : New tools and old barriers (pages 2531–2542)

      Isabel C. Scarinci, Francisco A.R. Garcia, Erin Kobetz, Edward E. Partridge, Heather M. Brandt, Maria C. Bell, Mark Dignan, Grace X. Ma, Jane L. Daye and Philip E. Castle

      Version of Record online: 22 MAR 2010 | DOI: 10.1002/cncr.25065

      • original image
      • original image

      Cervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80%) in the developing world. In the United States, in which the Papanicolaou test has reduced the annual incidence to approximately 11,000 cervical cancers, >60% of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Articles
    5. Original Articles
    6. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients (pages 2543–2548)

      Isabelle Bedrosian, Gildy V. Babiera, Elizabeth A. Mittendorf, Henry M. Kuerer, Laura Pantoja, Kelly K. Hunt, Savitri Krishnamurthy and Funda Meric-Bernstam

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25096

      • original image

      In breast cancer patients with cytologically documented, lymph node-positive disease, metastasis is noted to the axillary reverse mapping (ARM) lymph node in nearly 1 in 5 women. Therefore, in this population, ARM, performed to preserve the ipsilateral upper extremity lymphatic drainage, does not appear to be oncologically safe.

    2. You have free access to this content
      Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes : A population-based study and first report (pages 2549–2559)

      Mary Jo Lund, Ebonee N. Butler, Brionna Y. Hair, Kevin C. Ward, Judy H. Andrews, Gabriella Oprea-Ilies, A. Rana Bayakly, Ruth M. O'Regan, Paula M. Vertino and J. William Eley

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25016

      • original image

      HER2 recommendations are not uniformly adhered to and incidence rates for breast cancer triple subtypes differ by age/race. Rates can be cautiously extrapolated to an annual burden of HER2+ tumors among 3000 black women and 17,000 white women and triple negative tumors among 5000 black and 16,000 white women.

    3. Gastrointestinal Disease
      You have free access to this content
      Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer : A population-based study (pages 2560–2570)

      Joanne F. Chou, David Row, Mithat Gonen, Yi-Hai Liu, Deborah Schrag and Martin R. Weiser

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25032

      • original image

      The harvest of greater numbers of lymph nodes (LNs) after resection of colorectal cancer (CRC) has been associated with improved staging and outcome, which led the National Quality Forum to endorse the recommendation of examining at least 12 LNs from CRC specimens. However, heterogeneity in LN harvest exists and complicates the use of a single LN harvest cutoff point. In this study, the clinicopathologic factors associated with LN yield were investigated using the Surveillance, Epidemiology, and End Results database, which included 153,483 patients who were diagnosed between 1994 and 2005 with stage I, II, and III CRC.

    4. You have free access to this content
      Log odds of positive lymph nodes : A novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection (pages 2571–2580)

      Zhe Sun, Yan Xu, De Ming Li, Zhen Ning Wang, Guo Lian Zhu, Bao Jun Huang, Kai Li and Hui Mian Xu

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.24989

      • original image
      • original image
      • original image
      • original image

      The log odds of positive lymph nodes staging system has more potential of minimizing the “stage migration” phenomenon caused by insufficient lymph nodes retrieved and, consequently, is more reliable than the Union Internationale Contre le Cancer or American Joint Committee on cancer pN classification and rN classification for prognostic assessment.

    5. You have free access to this content
      Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro (pages 2581–2589)

      Marie Yeo, Hee Jin Park, Dong-Kyu Kim, Young Bae Kim, Jae Youn Cheong, Kwang Jae Lee and Sung Won Cho

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25003

      • original image
      • original image
      • original image
      • original image

      Loss of SM22 is a molecular signature of colon cancer and is closely associated with progression, differentiation, and metastasis of colon cancer. The restoration of SM22 leads to an inhibition of colon carcinogenesis in vivo and in vitro, suggesting that SM22 might potentially function as a novel tumor suppressor.

    6. Genitourinary Disease
      You have free access to this content
      Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer (pages 2590–2595)

      Karen E. Hoffman, Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Daniel Dosoretz, Sharon Salenius, Michael J. Katin, Rudi Ross and Anthony V. D'Amico

      Version of Record online: 22 MAR 2010 | DOI: 10.1002/cncr.24974

      • original image

      Elderly men without cardiovascular disease or with surgically corrected cardiovascular disease and high-risk prostate cancer had a lower risk of prostate cancer-specific mortality after combined treatment with brachytherapy, external-beam radiation therapy, and androgen-suppression therapy compared with brachytherapy alone. These results suggested that healthy older men benefit from aggressive treatment for high-risk prostate cancer.

    7. You have free access to this content
      The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer (pages 2596–2603)

      Rasanamar Sandhu, Chong-Xian Pan, Ted Wun, Danielle Harvey, Hong Zhou, Richard H. White and Helen K. Chew

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25004

      • original image
      • original image

      The authors investigated the incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer. A diagnosis of VTE after bladder cancer was identified as an independent risk factor for decreased survival within 2 years of bladder cancer diagnosis.

    8. You have free access to this content
      Patterns of care for early stage bladder cancer (pages 2604–2611)

      Seth A. Strope, Zaojun Ye, John M. Hollingsworth and Brent K. Hollenbeck

      Version of Record online: 22 MAR 2010 | DOI: 10.1002/cncr.25007

      • original image
      • original image
      • original image

      The average per capita expenditures for early stage bladder cancer care increased from $6,936 to $7,642 over the study period (10.2% increase; P < .01). However, up to 1 in 5 patients may receive too much or too little care, suggesting opportunities for improvement.

    9. You have free access to this content
      Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen : Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden (pages 2612–2620)

      Andrew J. Vickers, Angel M. Cronin, Gunnar Aus, Carl-Gustav Pihl, Charlotte Becker, Kim Pettersson, Peter T. Scardino, Jonas Hugosson and Hans Lilja

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25010

      • original image
      • original image
      • original image

      In an analysis of participants who underwent screening in the second or later rounds of the European Randomized Screening Study of Prostate Cancer, the authors observed that recent prostate-specific antigen (PSA) testing dramatically changed the performance of statistical models that predict biopsy outcomes. A 4-kallikrein panel was capable of predicting prostate cancer in men who had a recent screening history, and the results provided independent replication of the finding that multiple kallikrein forms contribute important diagnostic value in men with elevated PSA.

    10. Gynecologic Oncology
      You have free access to this content
      Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer (pages 2621–2634)

      Naomi Nakayama, Kentaro Nakayama, Yeasmin Shamima, Masako Ishikawa, Atsuko Katagiri, Kouji Iida and Khoji Miyazaki

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.24987

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      CCNE1 overexpression is critical to growth and survival of ovarian cancer tumors with CCNE1 gene amplification. CCNE1 silencing RNA-induced phenotypes depend on amplification status of ovarian cancers.

    11. Head and Neck Disease
      You have free access to this content
      Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population : The British Columbia experience (pages 2635–2644)

      Ajit Auluck, Greg Hislop, Chris Bajdik, Catherine Poh, Lewei Zhang and Miriam Rosin

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25087

      • original image
      • original image
      • original image
      • original image
      • original image

      Oropharyngeal cancer incidence has recently surpassed that of oral cavity cancer in men in British Columbia. South Asians and Chinese in British Columbia are at higher risk for cancers at both sites as compared with the general population.

    12. You have free access to this content
      Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status (pages 2645–2654)

      Asal Shoushtari, Mathew Meeneghan, Ke Sheng, Christopher A. Moskaluk, Christopher Y. Thomas, James F. Reibel, Paul A. Levine, Mark J. Jameson, Kimberly Keene and Paul W. Read

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25040

      • original image

      A retrospective analysis of 112 patients with oropharyngeal squamous cell carcinomas treated with intensity-modulated radiotherapy was performed. Patients were stratified by p16 status (which had previously been shown to be a surrogate marker for the human papillomavirus), neck dissection, and chemotherapy, and these factors were correlated with outcomes. p16 status was found to be a significant predictive biomarker, and patients with p16–positive tumors had much better outcomes than patients with p16–negative tumors.

    13. Hematologic Malignancies
      You have free access to this content
      Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma (pages 2655–2664)

      Jia Ruan, Peter Martin, Morton Coleman, Richard R. Furman, Ken Cheung, Adam Faye, Rebecca Elstrom, Mark Lachs, Katherine A. Hajjar and John P. Leonard

      Version of Record online: 16 MAR 2010 | DOI: 10.1002/cncr.25055

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen produced significant and durable clinical activity in patients with recurrent mantle cell lymphoma (MCL) while maintaining quality of life, in part by targeting lymphoma microenvironment and angiogenesis. Novel, low-intensity approaches warrant further evaluation in MCL and other lymphomas, either as part of a chronic maintenance treatment strategy or as initial therapy in elderly patients.

    14. You have free access to this content
      Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance (pages 2665–2672)

      Hagop Kantarjian, Phillipp le Coutre, Jorge Cortes, Javier Pinilla-Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura and Oliver Ottmann

      Version of Record online: 22 MAR 2010 | DOI: 10.1002/cncr.25079

      • original image
      • original image

      INNO-406, an oral dual Abl/Lyn kinase inhibitor, was tolerated at a dose of 240 mg twice daily in patients with Philadelphia chromosome-positive leukemias who were resistant to or intolerant of imatinib. INNO-406 had efficacy against chronic myeloid leukemia in this heavily pretreated study population and warrants further evaluation.

    15. You have free access to this content
      Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy (pages 2673–2681)

      Dushyant Verma, Hagop Kantarjian, Jianqin Shan, Susan O'Brien, Zeev Estrov, Guillermo Garcia-Manero, Charles Koller, Gautam Borthakur and Jorge Cortes

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25015

      • original image

      Clonal evolution in CML is a heterogeneous entity with variable outcome with second generation tyrosine kinase inhibitor therapy, with trisomy 8, chromosome 17, and complex abnormalities having the worst outcome, regardless of the number of metaphases involved.

    16. Lung Disease
      You have free access to this content
      KRAS mutation status in primary nonsmall cell lung cancer and matched metastases (pages 2682–2687)

      Alexis B. Cortot, Antoine Italiano, Fanny Burel-Vandenbos, Ghyslaine Martel-Planche and Pierre Hainaut

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25014

      • original image

      In this study, the mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) was compared between primary nonsmall cell lung cancers and matched metastases. The results indicated a high rate of concordance, although discordance between primary tumor and metastases remained in a few cases despite the use of a highly sensitive method for detecting mutations.

    17. Neuro-Oncology
      You have free access to this content
      Association between YKL-40 and adult primary astrocytoma (pages 2688–2697)

      Wei Zhang, Masahiko Kawanishi, Keisuke Miyake, Masahiro Kagawa, Nobuyuki Kawai, Koji Murao, Akira Nishiyama, Zhou Fei, Xiang Zhang and Takashi Tamiya

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25084

      • original image
      • original image
      • original image
      • original image
      • original image

      The data from this study revealed for the first time an indivisible relation between tumor cell expression of the YKL-40 coding chitinase 3-like 1 gene and World Health Organization grade of primary human astrocytomas. In addition, the pivotal role of YKL-40 was elucidated in glioma cell proliferation, including the possible pathway involved, which may provide a rationale for targeting YKL-40 as a novel therapeutic approach.

    18. Discipline

      Disparities Research
      You have free access to this content
      Race versus place of service in mortality among Medicare beneficiaries with cancer (pages 2698–2706)

      Tracy Onega, Eric J. Duell, Xun Shi, Eugene Demidenko and David C. Goodman

      Version of Record online: 22 MAR 2010 | DOI: 10.1002/cncr.25097

      • original image
      • original image

      Excess mortality among African-American cancer patients compared with Caucasian cancer patients in the Medicare population was observed overall but not among individuals who attended National Cancer Institute-designated comprehensive or clinical cancer centers. The current results indicated that place of service may explain some of the racial disparities in cancer outcomes.

    19. Symptom Control and Palliative Care
      You have free access to this content
      Risk factors for fatigue severity in primary brain tumor patients (pages 2707–2715)

      Terri S. Armstrong, Stanley G. Cron, Elizabeth Vera Bolanos, Mark R. Gilbert and Duck-Hee Kang

      Version of Record online: 16 MAR 2010 | DOI: 10.1002/cncr.25018

      Fatigue is a significant symptom for patients with primary brain tumors. Predictors of fatigue include performance status, sex, concomitant medications, and tumor grade.

    20. You have free access to this content
      Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life : Results from the Dutch Bone Metastasis Study (pages 2716–2725)

      Jan J. Meeuse, Yvette M. van der Linden, Geertjan van Tienhoven, Rijk O. B. Gans, Jan Willem H. Leer and An K. L. Reyners

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25062

      • original image
      • original image
      • original image

      Radiotherapy for painful bone metastases was effective in at least 45% of the patients who died within 12 weeks after randomization in the Dutch Bone Metastasis Study. For adequate pain control, additional palliative measures are essential.

  5. Errata

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Erratum (page 2726)

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25183

      • original image
      This article corrects:

      Circulating endothelial cells in patients with chronic lymphocytic leukemia

      Vol. 116, Issue 8, 1926–1937, Version of Record online: 17 FEB 2010

    2. You have free access to this content
      Erratum (page 2727)

      Version of Record online: 18 MAR 2010 | DOI: 10.1002/cncr.25182

      This article corrects:

      Multiple endocrine syndrome type 2B in early childhood

      Vol. 116, Issue 9, 2284, Version of Record online: 17 FEB 2010

SEARCH

SEARCH BY CITATION